1
|
Martin OA, Thomas M, Marquet M, Bruzeau C, Garot A, Brousse M, Bender S, Carrion C, Choi JE, Vuong BQ, Gearhart PJ, Maul RW, Le Noir S, Pinaud E. The IgH Eµ-MAR regions promote UNG-dependent error-prone repair to optimize somatic hypermutation. Front Immunol 2023; 14:1030813. [PMID: 36865553 PMCID: PMC9971809 DOI: 10.3389/fimmu.2023.1030813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 01/13/2023] [Indexed: 02/16/2023] Open
Abstract
Intoduction Two scaffold/matrix attachment regions (5'- and 3'-MARsEµ ) flank the intronic core enhancer (cEµ) within the immunoglobulin heavy chain locus (IgH). Besides their conservation in mice and humans, the physiological role of MARsEµ is still unclear and their involvement in somatic hypermutation (SHM) has never been deeply evaluated. Methods Our study analyzed SHM and its transcriptional control in a mouse model devoid of MARsEµ , further combined to relevant models deficient for base excision repair and mismatch repair. Results We observed an inverted substitution pattern in of MARsEµ -deficient animals: SHM being decreased upstream from cEµ and increased downstream of it. Strikingly, the SHM defect induced by MARsEµ -deletion was accompanied by an increase of sense transcription of the IgH V region, excluding a direct transcription-coupled effect. Interestingly, by breeding to DNA repair-deficient backgrounds, we showed that the SHM defect, observed upstream from cEµ in this model, was not due to a decrease in AID deamination but rather the consequence of a defect in base excision repair-associated unfaithful repair process. Discussion Our study pointed out an unexpected "fence" function of MARsEµ regions in limiting the error-prone repair machinery to the variable region of Ig gene loci.
Collapse
Affiliation(s)
- Ophélie A Martin
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Morgane Thomas
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Marie Marquet
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Charlotte Bruzeau
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Armand Garot
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Mylène Brousse
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Sébastien Bender
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France.,Centre Hospitalier Universitaire Dupuytren, Service d'Immunopathologie, Limoges, France
| | - Claire Carrion
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Jee Eun Choi
- The Graduate Center, The City University of New York, New York, NY, United States
| | - Bao Q Vuong
- The Graduate Center, The City University of New York, New York, NY, United States
| | - Patricia J Gearhart
- Laboratory of Molecular Biology and Immunology, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
| | - Robert W Maul
- Laboratory of Molecular Biology and Immunology, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
| | - Sandrine Le Noir
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| | - Eric Pinaud
- Laboratoire Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges, CNRS Unité Mixte de Recherche 7276, Inserm Unité 1262, Limoges, France
| |
Collapse
|
2
|
Zawil L, Marchiol T, Brauge B, Saintamand A, Carrion C, Dessauge E, Oblet C, Le Noir S, Mourcin F, Brousse M, Derouault P, Alizadeh M, Makhour YE, Monvoisin C, Saint-Vanne J, Léonard S, Durand-Panteix S, Tarte K, Cogné M. Distinct B-Cell Specific Transcriptional Contexts of the BCL2 Oncogene Impact Pre-Malignant Development in Mouse Models. Cancers (Basel) 2022; 14:cancers14215337. [PMID: 36358756 PMCID: PMC9654647 DOI: 10.3390/cancers14215337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 10/12/2022] [Accepted: 10/21/2022] [Indexed: 11/26/2022] Open
Abstract
Simple Summary Beyond the classical t(14;18) translocation associated with follicular lymphoma, BCL2 is deregulated in multiple B-cell malignancies, including some cases of myeloma, and through diverse genetic anomalies. It is currently unclear how the various deregulation patterns mechanistically impact the phenotype of theses malignancies. We designed two different BCL2 deregulation models in transgenic mice, whereby the oncogene was either associated with the IgH3′RR superenhancer, as in t(14;18), or inserted into the kappa light chain locus. We compared the impact of these models on B-cell fate and lymphoid tissues. Linkage to the IgH superenhancer showed a quite specific impact on germinal center B cell populations. The Ig kappa model was much less specific and strongly boosted the plasma cell in-flow and the accumulation of long-lived plasma cells. Abstract Upregulated expression of the anti-apoptotic BCL2 oncogene is a common feature of various types of B-cell malignancies, from lymphoma to leukemia or myeloma. It is currently unclear how the various patterns of deregulation observed in pathology eventually impact the phenotype of malignant B cells and their microenvironment. Follicular lymphoma (FL) is the most common non-Hodgkin lymphoma arising from malignant germinal center (GC) B-cells, and its major hallmark is the t(14:18) translocation occurring in B cell progenitors and placing the BCL2 gene under the control of the immunoglobulin heavy chain locus regulatory region (IgH 3′RR), thus exposing it to constitutive expression and hypermutation. Translocation of BCL2 onto Ig light chain genes, BCL2 gene amplification, and other mechanisms yielding BCL2 over-expression are, in contrast, rare in FL and rather promote other types of B-cell lymphoma, leukemia, or multiple myeloma. In order to assess the impact of distinct BCL2 deregulation patterns on B-cell fate, two mouse models were designed that associated BCL2 and its full P1-P2 promoter region to either the IgH 3′RR, within a “3′RR-BCL2” transgene mimicking the situation seen in FL, or an Ig light chain locus context, through knock-in insertion at the Igκ locus (“Igκ-BCL2” model). While linkage to the IgH 3′ RR mostly yielded expression in GC B-cells, the Igκ-driven up-regulation culminated in plasmablasts and plasma cells, boosting the plasma cell in-flow and the accumulation of long-lived plasma cells. These data demonstrate that the timing and level of BCL2 deregulation are crucial for the behavior of B cells inside GC, an observation that could strongly impact the lymphomagenesis process triggered by secondary genetic hits.
Collapse
Affiliation(s)
- Lina Zawil
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Tiffany Marchiol
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Baptiste Brauge
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
| | - Alexis Saintamand
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Claire Carrion
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Elise Dessauge
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
| | - Christelle Oblet
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Sandrine Le Noir
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Frédéric Mourcin
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
| | - Mylène Brousse
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | | | - Mehdi Alizadeh
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
| | - Yolla El Makhour
- Immunology Department, Science Faculty, Lebanese University, Beirut P.O. Box 6573/14, Lebanon
| | - Céline Monvoisin
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
| | - Julien Saint-Vanne
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
- Siti Laboratory, Chu Rennes, 35000 Rennes, France
| | - Simon Léonard
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, 44000 Nantes, France
| | - Stéphanie Durand-Panteix
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
| | - Karin Tarte
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
- Siti Laboratory, Chu Rennes, 35000 Rennes, France
- Correspondence: (K.T.); (M.C.)
| | - Michel Cogné
- Immunology Department, Faculty of Medicine, Limoges University, Cnrs Umr 7276, Inserm U1262, 2 Rue du Dr Marcland, 87000 Limoges, France
- UMR U 1236, Univ Rennes 1, INSERM, EFS Bretagne, Equipe Labellisée Ligue Contre le Cancer, 35000 Rennes, France
- Siti Laboratory, Chu Rennes, 35000 Rennes, France
- Correspondence: (K.T.); (M.C.)
| |
Collapse
|
3
|
Le Noir S, Boyer F, Lecardeur S, Brousse M, Oruc Z, Cook-Moreau J, Denizot Y, Cogné M. Functional anatomy of the immunoglobulin heavy chain 3΄ super-enhancer needs not only core enhancer elements but also their unique DNA context. Nucleic Acids Res 2017; 45:5829-5837. [PMID: 28369649 PMCID: PMC5449612 DOI: 10.1093/nar/gkx203] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 03/22/2017] [Indexed: 01/04/2023] Open
Abstract
Cis-regulatory elements feature clustered sites for transcription factors, defining core enhancers and have inter-species homology. The mouse IgH 3΄ regulatory region (3'RR), a major B-cell super-enhancer, consists of four of such core enhancers, scattered throughout more than 25 kb of packaging 'junk DNA', the sequence of which is not conserved but follows a unique palindromic architecture which is conserved in all mammalian species. The 3'RR promotes long-range interactions and potential IgH loops with upstream promoters, controlling class switch recombination (CSR) and somatic hypermutation (SHM). It was thus of interest to determine whether this functional architecture also involves the specific functional structure of the super-enhancer itself, potentially promoted by its symmetric DNA shell. Since many transgenic 3'RR models simply linked core enhancers without this shell, it was also important to compare such a 'core 3'RR' (c3'RR) with the intact full-length super-enhancer in an actual endogenous IgH context. Packaging DNA between 3'RR core enhancers proved in fact to be necessary for optimal SHM, CSR and IgH locus expression in plasma cells. This reveals that packaging DNA can matter in the functional anatomy of a super-enhancer, and that precise evaluation of such elements requires full consideration of their global architecture.
Collapse
Affiliation(s)
- Sandrine Le Noir
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - François Boyer
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Sandrine Lecardeur
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Mylène Brousse
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Zeliha Oruc
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Jeanne Cook-Moreau
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Yves Denizot
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France
| | - Michel Cogné
- UMR 7276 CNRS and Université de Limoges: Contrôle de la Réponse Immune B et Lymphoprolifération, 2 rue du Dr. Descottes, 87025 Limoges, France.,Institut Universitaire de France, Paris, France
| |
Collapse
|
10
|
Racle JP, Benkhadra A, Poy JY, Gantheret O, Poli L, Brousse M, Gleizal B. [Spinal anesthesia with bupivacaine for surgery of the hip in the elderly]. Ann Fr Anesth Reanim 1986; 5:490-6. [PMID: 3813145 DOI: 10.1016/s0750-7658(86)80035-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
In 60 elderly patients, spinal anaesthesia for orthopaedic hip surgery was induced randomly with 15 mg bupivacaine 0.375% without glucose (Group I), 2.5% glucose (Group II) or 7.5% glucose (Group III), in 4 ml. The injection was made in the lateral position, and the patients turned supine immediately after. The onset, extent and duration of sensory and motor blockade, the cardiovascular effects and the quality of anaesthesia were evaluated. The hyperbaric solutions produced a greater cephalad spread of analgesia (T8,9 and T9,8 respectively) than the glucose-free solution (T10,5). The mean duration of analgesia at the L2 level with the isobaric solution was significantly greater: 187 min versus 171 min and 150 min with the hyperbaric solutions. All the patients had complete motor blockade of the lower limb. The mean duration of the motor block was significantly shorter for the 2.5% and 7.5% glucose solutions (137 and 125 min respectively for Bromage's degree 3) versus 170 min for the glucose-free solution. Although the pre-anaesthetic arterial pressures in the three groups did not differ significantly, the systolic, mean and diastolic arterial pressures decreased only by about 20 to 25% in all groups. It was suggested to take into account the more rapid infusion of lactated Ringer's solution (20 ml X kg-1) in Group III. Anaesthesia was satisfactory in 95% of patients in Group I and Group II, and 90% in Group III. Glucose-free bupivacaine produced a long-lasting blockade suitable for hip surgery of long duration.
Collapse
|